|Dr. Werner Lanthaler||CEO & Member of Management Board||792k||N/A||1968|
|Mr. Enno Spillner||CFO & Member of Management Board||158k||N/A||1970|
|Dr. Mario Polywka||COO & Member of Management Board||614k||N/A||1963|
|Dr. Cord Dohrmann||Chief Scientific Officer & Member of Management Board||501k||N/A||1964|
|Ms. Anja Bosler||Principal Accounting Officer and Sr. VP of Group Accounting||N/A||N/A||N/A|
Evotec AG provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company operates through two segments, EVT Execute and EVT Innovate. It offers drug discovery services, such as integrated services, target identification and validation, hit identification, compound management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, cell and protein production, and in vivo and in vitro pharmacology services, as well as absorption, distribution, metabolism, excretion, and toxicity services. The company is also involved in investing and developing proprietary assets, including early-stage discovery programmes, as well as advanced drug candidates in the areas of diabetes and diabetic complications, inflammatory diseases, neuroscience, oncology, and pain and anti-infective. It has a strategic drug discovery and development partnership with Celgene Corporation to identify therapeutics in oncology. Evotec AG was founded in 1993 and is headquartered in Hamburg, Germany.
Evotec AG’s ISS Governance QualityScore as of July 1, 2018 is 6. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 1; Compensation: 10.